ヘリコバクターピロリfのスクリーニングと根絶,または胃がんの予防: 台北グローバルコンセンサスII
Jyh-Ming Liou1,2,3, Peter Malfertheiner4,5, Tzu-Chan Hong6,3
1Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan jyhmingliou@gmail.com e.el-omar@unsw.edu.au yichialee@ntu.edu.tw mingshiang@ntu.edu.tw.
Gut
|September 5, 2025
まとめ
ヘリコバクター・パイロリ (H. pylori) の根絶は,特にがん前疾患の発生前に,胃がんのリスクを大幅に低下させる. 世界的な専門家は,胃がんを予防するために,感染したすべての成人のために,H pyloriのスクリーニングと根絶を推奨しています.
科学分野:
- 胃腸内科と腫瘍科
- 感染症 疫学
- 公衆衛生政策
背景:
- ヘリコバクター・パイロリ (H. pylori) は胃がんの主な病因である.
- 効果的なスクリーニングと根絶戦略は胃がんの予防に不可欠です.
- 公共衛生の成果を最適化するために,H・パイロリ管理に関する世界的なコンセンサスが必要です.
研究 の 目的:
- 胃がんの予防のためのH・パイロリ検診と根絶に関する世界的なコンセンサスを確立する.
- H pyloriの管理における知識のギャップと将来の研究優先事項を特定する.
- GRADEフレームワークとデルフィーメソッドを用いて,証拠に基づいた勧告を精査する.
主な方法:
- 12カ国から32人の国際専門家を招集した.
- 評価,開発,評価の格付け (GRADE) フレームワークを利用した.
- デルフィ法で28の声明で80%以上のコンセンサスを達成した.
主要な成果:
- Hパイロリ根絶はあらゆる年齢層で胃がんのリスクを軽減し,最も効果的になるのが前発性疾患です.
- 13C尿素の呼吸や便の抗原検査を用いた高リスク集団のスクリーニングが推奨される.
- 高抗生物質耐性地域における経験的四重治療と根絶後の確認試験に推奨される.
結論:
- 胃がんの予防には有効な戦略であり,感染したすべての成人に提供されるべきです.
- 将来の研究は,最適なスクリーニングタイミング,長期的な結果,高度なリスクの階層化に焦点を当てるべきです.
- H pylori のワクチンの開発は,まだ満たされていない重大な需要です.
関連する概念動画
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
546
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
193
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
193
01:26Peptic Ulcer Disease IV: Management
144
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
144
01:30Peptic Ulcer Disease I: Introduction
282
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
282
01:23Gastritis III: Clinical Manifestations and Management
462
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
462
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
518
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
518